Lexaria Bioscience Corp. Files 8-K: Board Changes & Officer Compensation

Ticker: LEXX · Form: 8-K · Filed: Jul 17, 2024

Sentiment: neutral

Topics: board-changes, officer-compensation, regulation-fd

Related Tickers: LXRP

TL;DR

Lexaria board shakeup and new exec pay details dropped in 8-K.

AI Summary

Lexaria Bioscience Corp. announced on July 15, 2024, a change in its board of directors, including the election of new directors and the appointment of certain officers. The company also disclosed compensatory arrangements for its officers and provided financial statements and exhibits as part of this Form 8-K filing.

Why It Matters

Changes in board composition and officer compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Board changes and executive compensation disclosures can sometimes precede significant strategic shifts or reflect internal dynamics that may pose risks.

Key Players & Entities

Lexaria Bioscience Corp. (company) — Registrant
July 15, 2024 (date) — Date of earliest event reported
Nevada (jurisdiction) — State of incorporation

FAQ

What specific changes were made to the board of directors?

The filing indicates the election of directors and appointment of certain officers, but the specific names and details of the changes are not provided in this excerpt.

What type of compensatory arrangements were disclosed for officers?

The filing mentions 'Compensatory Arrangements of Certain Officers' as an item, but the specific details of these arrangements are not included in this excerpt.

What is the exact date of the earliest event reported in this 8-K?

The earliest event reported is dated July 15, 2024.

In which U.S. state was Lexaria Bioscience Corp. incorporated?

Lexaria Bioscience Corp. was incorporated in Nevada.

What is the SIC code for Lexaria Bioscience Corp.?

The Standard Industrial Classification (SIC) code for Lexaria Bioscience Corp. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 665 words · 3 min read · ~2 pages · Grade level 12.9 · Accepted 2024-07-17 16:12:18

Key Financial Figures

$0.001 — ch registered Common Stock, par value $0.001 per share Warrants to Purchase Common

Filing Documents

lxrp_8k.htm (8-K) — 27KB
lxrp_ex991.htm (EX-99.1) — 40KB
lxrp_ex991img6.jpg (GRAPHIC) — 3KB
lxrp_ex991img2.jpg (GRAPHIC) — 26KB
lxrp_ex991img3.jpg (GRAPHIC) — 3KB
lxrp_ex991img4.jpg (GRAPHIC) — 3KB
lxrp_ex991img5.jpg (GRAPHIC) — 3KB
0001640334-24-001132.txt ( ) — 270KB
lxrp-20240715.xsd (EX-101.SCH) — 6KB
lxrp-20240715_lab.xml (EX-101.LAB) — 16KB
lxrp-20240715_cal.xml (EX-101.CAL) — 1KB
lxrp-20240715_pre.xml (EX-101.PRE) — 12KB
lxrp-20240715_def.xml (EX-101.DEF) — 5KB
lxrp_8k_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On July 17, 2024 the Company announced initial results from eight of its twelve arm animal study WEIGHT-A24-1 whereby it has been found that DehydraTECH works with a second GLP-1 drug, liraglutide, works with semaglutide both with and without SNAC technology and that DehydraTECH-CBD is performing strongly against these GLP-1 drugs. The results from the initial eight study arms which tested DehydraTECH enhanced: CBD, Rybelsus, semaglutide and liraglutide were used to determine the strongest performers for the purposes of creating a combined DehydraTECH-semaglutide with DehydraTECH-CBD formulation and a combined DehydraTECH-liraglutide with DehydraTECH-CBD for the second portion of the study which has commenced with results expected to be completed in mid-October.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits 99.1 Press Release dated July 17, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEXARIA BIOSCIENCE CORP. /s/ Chris Bunka Chris Bunka CEO, Principal Executive Officer Date: July 17, 2024 3